Plasma Proteomics for the Identification of Alzheimer Disease
暂无分享,去创建一个
Stefan Wagenpfeil | Robert Perneczky | Panagiotis Alexopoulos | A. Kurz | R. Perneczky | P. Alexopoulos | S. Wagenpfeil | Alexander Kurz | Liang-Hao Guo | Liang-Hao Guo
[1] Henrik Zetterberg,et al. Low Incidence of Post-Lumbar Puncture Headache in 1,089 Consecutive Memory Clinic Patients , 2010, European Neurology.
[2] S. Lovestone,et al. Proteome-based plasma biomarkers for Alzheimer's disease. , 2006, Brain : a journal of neurology.
[3] P. Visca,et al. Hemoglobin and heme scavenging , 2005, IUBMB life.
[4] Monique Breteler,et al. Identifying Early Markers of Alzheimer's Disease using Quantitative Multiplex Proteomic Immunoassay Panels , 2009, Annals of the New York Academy of Sciences.
[5] J. Szaflarski,et al. Human blood genomics: distinct profiles for gender, age and neurofibromatosis type 1. , 2004, Brain research. Molecular brain research.
[6] M. Riemenschneider. Diagnosis of Alzheimer's disease with cerebrospinal fluid tau protein and aspartate aminotransferase , 1998, The Lancet.
[7] H. Schluesener,et al. Expression of interleukin-16 by microglial cells in inflammatory, autoimmune, and degenerative lesions of the rat brain , 2004, Journal of Neuroimmunology.
[8] A. Hofman,et al. Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. , 2004, Archives of neurology.
[9] C. Rowe,et al. Plasma apolipoprotein E and Alzheimer disease risk , 2011, Neurology.
[10] H. Hampel,et al. Total and Phosphorylated Tau Proteins: Evaluation as Core Biomarker Candidates in Frontotemporal Dementia , 2004, Dementia and Geriatric Cognitive Disorders.
[11] Yuan Qi,et al. Identifying Neuroimaging and Proteomic Biomarkers for MCI and AD via the Elastic Net , 2011, MBIA.
[12] E. Umlauf,et al. The role of proteomics in dementia and Alzheimer’s disease , 2009, Acta Neuropathologica.
[13] Hirotoshi Watanabe,et al. Clinical impression of brain natriuretic peptide levels in demented patients without cardiovascular disease , 2009, Geriatrics & gerontology international.
[14] J. Broderick,et al. Effects of Gender on Gene Expression in the Blood of Ischemic Stroke Patients , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[15] G. Siest,et al. Apolipoprotein E Polymorphism and Serum Concentration in Alzheimer's Disease in Nine European Centres: the ApoEurope Study , 2000, Clinical chemistry and laboratory medicine.
[16] Giuseppe Banfi,et al. Metabolic markers in sports medicine. , 2012, Advances in clinical chemistry.
[17] Werner Zolg,et al. The Proteomic Search for Diagnostic Biomarkers , 2006, Molecular & Cellular Proteomics.
[18] K. Rufibach,et al. Modeling of Pathological Traits in Alzheimer's Disease Based on Systemic Extracellular Signaling Proteome* , 2011, Molecular & Cellular Proteomics.
[19] Yi Zhang,et al. Plasma Biomarkers of Brain Atrophy in Alzheimer's Disease , 2011, PloS one.
[20] R. Tibshirani,et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.
[21] A. Smilde,et al. Statistical data processing in clinical proteomics. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[22] P. Moscato,et al. Differences in Abundances of Cell-Signalling Proteins in Blood Reveal Novel Biomarkers for Early Detection Of Clinical Alzheimer's Disease , 2011, PloS one.
[23] Christoph Laske,et al. Identification of a blood-based biomarker panel for classification of Alzheimer's disease. , 2011, The international journal of neuropsychopharmacology.
[24] Eileen Daly,et al. Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer’s disease , 2008, Journal of Neurology.
[25] F. Jessen,et al. Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease , 2012, Neurology.
[26] Guanghua Xiao,et al. A Blood-Based Screening Tool for Alzheimer's Disease That Spans Serum and Plasma: Findings from TARC and ADNI , 2011, PloS one.
[27] P. Lewczuk,et al. Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. , 2008, Methods.
[28] A. Kurz,et al. Apolipoprotein E epsilon 4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease , 1996, Neurology.
[29] A. Roses,et al. The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone. , 2008, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[30] S. Bunge,et al. Blood gene expression correlated with tic severity in medicated and unmedicated patients with Tourette Syndrome. , 2010, Pharmacogenomics.
[31] Thomas Arendt,et al. Synaptic degeneration in Alzheimer’s disease , 2009, Acta Neuropathologica.
[32] D. Holtzman,et al. Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance , 2009, Neuron.
[33] Katharina Buerger,et al. Biological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and Serum , 2009, CNS neuroscience & therapeutics.
[34] P. Deyn,et al. Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.
[35] Guanghua Xiao,et al. A serum protein-based algorithm for the detection of Alzheimer disease. , 2010, Archives of neurology.
[36] Min Shi,et al. Biomarker discovery in neurodegenerative diseases: A proteomic approach , 2009, Neurobiology of Disease.
[37] Wei Li,et al. The mechanism for heme to prevent Aβ1–40 aggregation and its cytotoxicity , 2011, JBIC Journal of Biological Inorganic Chemistry.
[38] Vincenzo Savarino,et al. Liver enzyme alteration: a guide for clinicians , 2005, Canadian Medical Association Journal.
[39] Kevin Taddei,et al. Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease , 1997, Neuroscience Letters.
[40] G. Fisher,et al. Amino acids and transaminases activity in ventricular CSF and in brain of normal and Alzheimer patients , 2005, Neuroscience Letters.
[41] Nick C Fox,et al. The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.
[42] M. Martini,et al. Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease , 1999, Neuroscience Letters.
[43] S. Potkin,et al. Genome-wide association study of CSF biomarkers Aβ1-42, t-tau, and p-tau181p in the ADNI cohort , 2010, Neurology.
[44] Hans Förstl,et al. CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease , 2011, Neurology.
[45] Tony Wyss-Coray,et al. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? , 2006, Nature Medicine.
[46] J. Rockstroh,et al. Biomarkers of fibrosis and impaired liver function in chronic hepatitis C: how well do they predict clinical outcomes? , 2010, Current opinion in HIV and AIDS.
[47] F. Nicoletti,et al. Chitotriosidase and inflammatory mediator levels in Alzheimer's disease and cerebrovascular dementia , 2006, The European journal of neuroscience.
[48] Xiaojing Sui,et al. Cerebrospinal fluid biomarkers of Alzheimer’s disease , 2014, Neuroscience Bulletin.
[49] A. Ortqvist,et al. Pneumocystis carinii pneumonia in Stockholm, Sweden: treatment, outcome, one-year-follow-up and pyrimethamine prophylaxis. , 1989, Scandinavian journal of infectious diseases.
[50] K. Dietz,et al. Expression of interleukin-16 by tumor-associated macrophages/activated microglia in high-grade astrocytic brain tumors , 2007, Archivum Immunologiae et Therapiae Experimentalis.
[51] M. Weiner,et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.
[52] A. Passaro,et al. Markers of endothelial dysfunction in older subjects with late onset Alzheimer's disease or vascular dementia , 2008, Journal of the Neurological Sciences.
[53] Madhav Thambisetty,et al. Blood-based biomarkers of Alzheimer's disease: challenging but feasible. , 2010, Biomarkers in medicine.
[54] P. Liao,et al. Proteomics analysis of plasma for potential biomarkers in the diagnosis of Alzheimer's disease , 2007, Proteomics. Clinical applications.
[55] A. Wu. Cardiac markers: from enzymes to proteins, diagnosis to prognosis, laboratory to bedside. , 1999, Annals of clinical and laboratory science.
[56] Markus Schwaiger,et al. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer’s disease , 2008, NeuroImage.
[57] Georg Kemmler,et al. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease , 2011, Neurobiology of Aging.
[58] J. Morris,et al. Validation of clinical diagnostic criteria for Alzheimer's disease , 1988, Annals of neurology.
[59] C. Schaefer,et al. Analysis of the human serum proteome , 2004, Clinical Proteomics.
[60] John D. Storey,et al. Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[61] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .